Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial



Pettitt, Andrew R, Jackson, Richard, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Polydoros, Fotis, Yap, Christina, Dodd, James, Bickerstaff, Matthew, Stackpoole, Michael, Khan, Umair T ORCID: 0000-0002-9470-3481, Carruthers, Stacey
et al (show 16 more authors) (2020) Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105 (12). 2868 - 2871.

[img] Text
CLL210 manuscript letter to editor.docx - Accepted Version

Download (628kB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 07 May 2020 09:43
Last Modified: 23 Oct 2021 07:11
DOI: 10.3324/haematol.2019.230805
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3086357